PD-L1 inhibitors in the pipeline: Promise and progress
| Autor: | Ester Simeone, Antonio M. Grimaldi, Martina Strudel, Vito Vanella, Lucia Festino, Paolo A. Ascierto |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
atezolizumab
lcsh:Immunologic diseases. Allergy 0301 basic medicine Oncology medicine.medical_specialty Durvalumab durvalumab medicine.medical_treatment Immunology Review lcsh:RC254-282 merkel cell carcinoma Avelumab 03 medical and health sciences 0302 clinical medicine pd-l1 Atezolizumab PD-L1 Internal medicine melanoma Immunology and Allergy Medicine Lung cancer Bladder cancer biology business.industry Melanoma Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease lung cancer 030104 developmental biology 030220 oncology & carcinogenesis biology.protein bladder cancer avelumab immunotherapy lcsh:RC581-607 business medicine.drug |
| Zdroj: | OncoImmunology, Vol 7, Iss 1 (2018) |
| ISSN: | 2162-402X |
| Popis: | Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compared with anti-CTLA-4 drugs, studies with anti-PD-1/PD-L1 agents have suggested higher response rates and improved survival. Targeting PD-L1 rather than PD-1 may also theoretically offer further benefit, with the potential for improved efficacy and reduced toxicity, although this has not been clearly shown by clinical experience to date. Anti-PD-L1 agents have shown good efficacy and manageable toxicity in several tumor types. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|